Atlas Trials

Phase 1

20 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Phase 1

RecordFirmDate
Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects (NCT05068947)Graviton Bioscience Corporation2021-09-10
Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects (NCT04327089)Calliditas Therapeutics AB2020-06-24
A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies (NCT04014257)Handok Inc.2019-08-09
PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI) (NCT03983876)Alvotech Swiss AG2019-07-01
Safety Study of Dengushield in Healthy Adults (NCT03883620)Serum Institute of India Pvt. Ltd.2019-03-22
Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets (NCT03740217)Calliditas Therapeutics AB2018-12-19
A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate (NCT03488719)Saniona2018-07-11
A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers (NCT03647670)Pfizer2018-07-03
Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects (NCT03273088)AryoGen Pharmed Co.2016-12-04
A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects (NCT03273192)Cinnagen2016-10-22
A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels (NCT02010944)Astellas Pharma Europe B.V.2012-09-01
A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. (NCT01415102)Pfizer2010-09-01
A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects. (NCT01091532)Pfizer2010-03-01
EC905 Pharmacokinetic Profile Study (NCT02634489)Astellas Pharma Europe B.V.2009-03-01

Track Phase 1 automatically

Every clearance here is in the API, with alerts when new ones post.